ReviewFrontiers in microbiology2021
The Use of Fecal Microbiome Transplant in Treating Human Diseases: Too Early for Poop?
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 57 citations in OpenAlex.
- Emerging Therapeutic Approaches for Modulating the Intestinal Microbiota.Pharmaceutics · 2026Review
- Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies.Frontiers in allergy · 2026Review
- An overview of the role of the gut microbiota in rheumatoid arthritis.Microbiome research reports · 2026Review
- A novel framework for assessing causal effect of microbiome on health: long-term antibiotic usage as an instrument.Gut microbes · 2025Article
- The role of fecal microbiota transplantation in diabetes.Acta diabetologica · 2025Review
- Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.BMC complementary medicine and therapies · 2025Article
- Dysbiosis and Regulation of Gut Microbiota in Type 2 Diabetes Mellitus.Current pharmaceutical biotechnology · 2025Review
- A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for RecurrentAntibiotics (Basel, Switzerland) · 2024Review
- Understanding the factors regulating host-microbiome interactions usingPhilosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Review
- Clinical evidence of the link between gut microbiome and myalgic encephalomyelitis/chronic fatigue syndrome: a retrospective review.European journal of medical research · 2024Review
- Gynecological Cancers and Microbiota Dynamics: Insights into Pathogenesis and Therapy.International journal of molecular sciences · 2024Review
- Effects of Artemisia asiatica ex on Akkermansia muciniphila dominance for modulation of Alzheimer's disease in mice.PloS one · 2024Article
- Therapeutic targeting of obesity-induced neuroinflammation and neurodegeneration.Frontiers in endocrinology · 2024Review
- Prebiotic Cellulose-Pullulan Matrix as a "Vehicle" for Probiotic Biofilm Delivery to the Host Large Intestine.Polymers · 2023Article
- Drug-microbiota interactions: an emerging priority for precision medicine.Signal transduction and targeted therapy · 2023Review
- Gut Microbiome Transplants and Their Health Impacts across Species.Microorganisms · 2023Review
- The oral microbiome in the pathophysiology of cardiovascular disease.Nature reviews. Cardiology · 2023Review
- Recruitment of the rhizo-microbiome army: assembly determinants and engineering of the rhizosphere microbiome as a key to unlocking plant potential.Frontiers in microbiology · 2023Review
- Revolutionized virome research using systems microbiology approaches.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Population bottlenecks constrain host microbiome diversity and genetic variation impeding fitness.PLoS genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fecal microbiome transplant (FMT) has gained popularity over the past few years, given its success in treating several gastrointestinal diseases. At the same time, microbial populations in the gut have been shown to have more physiological effects than we expected as "habitants" of the gut. The imbalance in the gut microbiome or dysbiosis, particularly when there are excessive harmful pathogens, can trigger not just infections but can also result in the development of common diseases, such as cancer and cardiometabolic diseases. By using FMT technology, the dysbiosis of the gut microbiome in patients can be resolved by administering fecal materials from a healthy donor. The current review summarizes the history and current uses of FMT before suggesting potential ideas for its high-quality application in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.